Covid-19 Impact on Global Influenza (Flu) Antiviral Drugs Market Size, Status and Forecast 2020-2026

June 2020 | 132 pages | ID: C79230547A15EN
QYResearch

Abstracts

This report focuses on the global Influenza (Flu) Antiviral Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Influenza (Flu) Antiviral Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Pfizer
• Roche
• Sanofi
• Johnson & Johnson
• Merck & Co. (MSD)
• Novartis
• AbbVie
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Amgen
• AstraZeneca
• Bristol-Myers Squibb
• Eli Lilly
• Teva
• Bayer
• Novo Nordisk
• Allergan
• Takeda
• Boehringer Ingelheim

Market segment by Type, the product can be split into

• Penetration and Dehulling Inhibitors
• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protein Inhibitors
• Neuraminidase Inhibitors
• Broad-spectrum Antiviral Drugs

Market segment by Application, split into

• Hospital
• Clinic
• Household
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Influenza (Flu) Antiviral Drugs status, future forecast, growth opportunity, key market and key players.
• To present the Influenza (Flu) Antiviral Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Influenza (Flu) Antiviral Drugs are as follows:
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Influenza (Flu) Antiviral Drugs Revenue
1.4 Covid-19 Implications on Market by Type
  1.4.1 Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Penetration and Dehulling Inhibitors
  1.4.3 DNA Polymerase Inhibitors
  1.4.4 Reverse Transcriptase Inhibitors
  1.4.5 Protein Inhibitors
  1.4.6 Neuraminidase Inhibitors
  1.4.7 Broad-spectrum Antiviral Drugs
1.5 Covid-19 Implications on Market by Application
  1.5.1 Global Influenza (Flu) Antiviral Drugs Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Clinic
  1.5.4 Household
  1.5.5 Others
1.6 Coronavirus Disease 2019 (Covid-19): Influenza (Flu) Antiviral Drugs Industry Impact
  1.6.1 How the Covid-19 is Affecting the Influenza (Flu) Antiviral Drugs Industry
    1.6.1.1 Influenza (Flu) Antiviral Drugs Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Influenza (Flu) Antiviral Drugs Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Influenza (Flu) Antiviral Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Covid-19 Implications on Global Influenza (Flu) Antiviral Drugs Market Perspective (2015-2026)
2.2 Covid-19 Implications on Global Influenza (Flu) Antiviral Drugs Growth Trends by Regions
  2.2.1 Influenza (Flu) Antiviral Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Influenza (Flu) Antiviral Drugs Historic Market Share by Regions (2015-2020)
  2.2.3 Influenza (Flu) Antiviral Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Influenza (Flu) Antiviral Drugs Market Growth Strategy
  2.3.6 Primary Interviews with Key Influenza (Flu) Antiviral Drugs Players (Opinion Leaders)

3 COVID-19 IMPLICATIONS ON COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Influenza (Flu) Antiviral Drugs Players by Market Size
  3.1.1 Global Top Influenza (Flu) Antiviral Drugs Players by Revenue (2015-2020)
  3.1.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Players (2015-2020)
  3.1.3 Global Influenza (Flu) Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio
  3.2.1 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Influenza (Flu) Antiviral Drugs Revenue in 2019
3.3 Influenza (Flu) Antiviral Drugs Key Players Head office and Area Served
3.4 Key Players Influenza (Flu) Antiviral Drugs Product Solution and Service
3.5 Date of Enter into Influenza (Flu) Antiviral Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 COVID-19 IMPLICATIONS ON MARKET SIZE BY TYPE (2015-2026)

4.1 Global Influenza (Flu) Antiviral Drugs Historic Market Size by Type (2015-2020)
4.2 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Type (2021-2026)

5 COVID-19 IMPLICATIONS ON MARKET SIZE BY APPLICATION (2015-2026)

5.1 Global Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020)
5.2 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Influenza (Flu) Antiviral Drugs Market Size (2015-2020)
6.2 Influenza (Flu) Antiviral Drugs Key Players in North America (2019-2020)
6.3 North America Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020)
6.4 North America Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Influenza (Flu) Antiviral Drugs Market Size (2015-2020)
7.2 Influenza (Flu) Antiviral Drugs Key Players in Europe (2019-2020)
7.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020)
7.4 Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020)

8 CHINA

8.1 China Influenza (Flu) Antiviral Drugs Market Size (2015-2020)
8.2 Influenza (Flu) Antiviral Drugs Key Players in China (2019-2020)
8.3 China Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020)
8.4 China Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Influenza (Flu) Antiviral Drugs Market Size (2015-2020)
9.2 Influenza (Flu) Antiviral Drugs Key Players in Japan (2019-2020)
9.3 Japan Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020)
9.4 Japan Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Influenza (Flu) Antiviral Drugs Market Size (2015-2020)
10.2 Influenza (Flu) Antiviral Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020)

11 INDIA

11.1 India Influenza (Flu) Antiviral Drugs Market Size (2015-2020)
11.2 Influenza (Flu) Antiviral Drugs Key Players in India (2019-2020)
11.3 India Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020)
11.4 India Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Influenza (Flu) Antiviral Drugs Market Size (2015-2020)
12.2 Influenza (Flu) Antiviral Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020)
12.4 Central & South America Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020)

13KEY PLAYERS PROFILES

13.1 Pfizer
  13.1.1 Pfizer Company Details
  13.1.2 Pfizer Business Overview and Its Total Revenue
  13.1.3 Pfizer Influenza (Flu) Antiviral Drugs Introduction
  13.1.4 Pfizer Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020))
  13.1.5 Pfizer Recent Development
13.2 Roche
  13.2.1 Roche Company Details
  13.2.2 Roche Business Overview and Its Total Revenue
  13.2.3 Roche Influenza (Flu) Antiviral Drugs Introduction
  13.2.4 Roche Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  13.2.5 Roche Recent Development
13.3 Sanofi
  13.3.1 Sanofi Company Details
  13.3.2 Sanofi Business Overview and Its Total Revenue
  13.3.3 Sanofi Influenza (Flu) Antiviral Drugs Introduction
  13.3.4 Sanofi Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  13.3.5 Sanofi Recent Development
13.4 Johnson & Johnson
  13.4.1 Johnson & Johnson Company Details
  13.4.2 Johnson & Johnson Business Overview and Its Total Revenue
  13.4.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Introduction
  13.4.4 Johnson & Johnson Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  13.4.5 Johnson & Johnson Recent Development
13.5 Merck & Co. (MSD)
  13.5.1 Merck & Co. (MSD) Company Details
  13.5.2 Merck & Co. (MSD) Business Overview and Its Total Revenue
  13.5.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Introduction
  13.5.4 Merck & Co. (MSD) Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  13.5.5 Merck & Co. (MSD) Recent Development
13.6 Novartis
  13.6.1 Novartis Company Details
  13.6.2 Novartis Business Overview and Its Total Revenue
  13.6.3 Novartis Influenza (Flu) Antiviral Drugs Introduction
  13.6.4 Novartis Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  13.6.5 Novartis Recent Development
13.7 AbbVie
  13.7.1 AbbVie Company Details
  13.7.2 AbbVie Business Overview and Its Total Revenue
  13.7.3 AbbVie Influenza (Flu) Antiviral Drugs Introduction
  13.7.4 AbbVie Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  13.7.5 AbbVie Recent Development
13.8 Gilead Sciences
  13.8.1 Gilead Sciences Company Details
  13.8.2 Gilead Sciences Business Overview and Its Total Revenue
  13.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Introduction
  13.8.4 Gilead Sciences Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  13.8.5 Gilead Sciences Recent Development
13.9 GlaxoSmithKline (GSK)
  13.9.1 GlaxoSmithKline (GSK) Company Details
  13.9.2 GlaxoSmithKline (GSK) Business Overview and Its Total Revenue
  13.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Introduction
  13.9.4 GlaxoSmithKline (GSK) Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  13.9.5 GlaxoSmithKline (GSK) Recent Development
13.10 Amgen
  13.10.1 Amgen Company Details
  13.10.2 Amgen Business Overview and Its Total Revenue
  13.10.3 Amgen Influenza (Flu) Antiviral Drugs Introduction
  13.10.4 Amgen Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  13.10.5 Amgen Recent Development
13.11 AstraZeneca
  10.11.1 AstraZeneca Company Details
  10.11.2 AstraZeneca Business Overview and Its Total Revenue
  10.11.3 AstraZeneca Influenza (Flu) Antiviral Drugs Introduction
  10.11.4 AstraZeneca Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  10.11.5 AstraZeneca Recent Development
13.12 Bristol-Myers Squibb
  10.12.1 Bristol-Myers Squibb Company Details
  10.12.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  10.12.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Introduction
  10.12.4 Bristol-Myers Squibb Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  10.12.5 Bristol-Myers Squibb Recent Development
13.13 Eli Lilly
  10.13.1 Eli Lilly Company Details
  10.13.2 Eli Lilly Business Overview and Its Total Revenue
  10.13.3 Eli Lilly Influenza (Flu) Antiviral Drugs Introduction
  10.13.4 Eli Lilly Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  10.13.5 Eli Lilly Recent Development
13.14 Teva
  10.14.1 Teva Company Details
  10.14.2 Teva Business Overview and Its Total Revenue
  10.14.3 Teva Influenza (Flu) Antiviral Drugs Introduction
  10.14.4 Teva Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  10.14.5 Teva Recent Development
13.15 Bayer
  10.15.1 Bayer Company Details
  10.15.2 Bayer Business Overview and Its Total Revenue
  10.15.3 Bayer Influenza (Flu) Antiviral Drugs Introduction
  10.15.4 Bayer Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  10.15.5 Bayer Recent Development
13.16 Novo Nordisk
  10.16.1 Novo Nordisk Company Details
  10.16.2 Novo Nordisk Business Overview and Its Total Revenue
  10.16.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Introduction
  10.16.4 Novo Nordisk Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  10.16.5 Novo Nordisk Recent Development
13.17 Allergan
  10.17.1 Allergan Company Details
  10.17.2 Allergan Business Overview and Its Total Revenue
  10.17.3 Allergan Influenza (Flu) Antiviral Drugs Introduction
  10.17.4 Allergan Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  10.17.5 Allergan Recent Development
13.18 Takeda
  10.18.1 Takeda Company Details
  10.18.2 Takeda Business Overview and Its Total Revenue
  10.18.3 Takeda Influenza (Flu) Antiviral Drugs Introduction
  10.18.4 Takeda Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  10.18.5 Takeda Recent Development
13.19 Boehringer Ingelheim
  10.19.1 Boehringer Ingelheim Company Details
  10.19.2 Boehringer Ingelheim Business Overview and Its Total Revenue
  10.19.3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Introduction
  10.19.4 Boehringer Ingelheim Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020)
  10.19.5 Boehringer Ingelheim Recent Development

14ANALYST'S VIEWPOINTS/CONCLUSIONS

15APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Influenza (Flu) Antiviral Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Influenza (Flu) Antiviral Drugs Revenue
Table 3. Ranking of Global Top Influenza (Flu) Antiviral Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Penetration and Dehulling Inhibitors
Table 6. Key Players of DNA Polymerase Inhibitors
Table 7. Key Players of Reverse Transcriptase Inhibitors
Table 8. Key Players of Protein Inhibitors
Table 9. Key Players of Neuraminidase Inhibitors
Table 10. Key Players of Broad-spectrum Antiviral Drugs
Table 11. COVID-19 Impact Global Market: (Four Influenza (Flu) Antiviral Drugs Market Size Forecast Scenarios)
Table 12. Opportunities and Trends for Influenza (Flu) Antiviral Drugs Players in the COVID-19 Landscape
Table 13. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 14. Key Regions/Countries Measures against Covid-19 Impact
Table 15. Proposal for Influenza (Flu) Antiviral Drugs Players to Combat Covid-19 Impact
Table 16. Global Influenza (Flu) Antiviral Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 17. Global Influenza (Flu) Antiviral Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 18. Global Influenza (Flu) Antiviral Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 19. Global Influenza (Flu) Antiviral Drugs Market Share by Regions (2015-2020)
Table 20. Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 21. Global Influenza (Flu) Antiviral Drugs Market Share by Regions (2021-2026)
Table 22. Market Top Trends
Table 23. Key Drivers: Impact Analysis
Table 24. Key Challenges
Table 25. Influenza (Flu) Antiviral Drugs Market Growth Strategy
Table 26. Main Points Interviewed from Key Influenza (Flu) Antiviral Drugs Players
Table 27. Global Influenza (Flu) Antiviral Drugs Revenue by Players (2015-2020) (Million US$)
Table 28. Global Influenza (Flu) Antiviral Drugs Market Share by Players (2015-2020)
Table 29. Global Top Influenza (Flu) Antiviral Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Influenza (Flu) Antiviral Drugs as of 2019)
Table 30. Global Influenza (Flu) Antiviral Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 31. Key Players Headquarters and Area Served
Table 32. Key Players Influenza (Flu) Antiviral Drugs Product Solution and Service
Table 33. Date of Enter into Influenza (Flu) Antiviral Drugs Market
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020) (Million US$)
Table 36. Global Influenza (Flu) Antiviral Drugs Market Size Share by Type (2015-2020)
Table 37. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2026)
Table 38. Global Influenza (Flu) Antiviral Drugs Market Size Share by Application (2015-2020)
Table 39. Global Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020) (Million US$)
Table 40. Global Influenza (Flu) Antiviral Drugs Market Size Share by Application (2021-2026)
Table 41. North America Key Players Influenza (Flu) Antiviral Drugs Revenue (2019-2020) (Million US$)
Table 42. North America Key Players Influenza (Flu) Antiviral Drugs Market Share (2019-2020)
Table 43. North America Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020) (Million US$)
Table 44. North America Influenza (Flu) Antiviral Drugs Market Share by Type (2015-2020)
Table 45. North America Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020) (Million US$)
Table 46. North America Influenza (Flu) Antiviral Drugs Market Share by Application (2015-2020)
Table 47. Europe Key Players Influenza (Flu) Antiviral Drugs Revenue (2019-2020) (Million US$)
Table 48. Europe Key Players Influenza (Flu) Antiviral Drugs Market Share (2019-2020)
Table 49. Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020) (Million US$)
Table 50. Europe Influenza (Flu) Antiviral Drugs Market Share by Type (2015-2020)
Table 51. Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020) (Million US$)
Table 52. Europe Influenza (Flu) Antiviral Drugs Market Share by Application (2015-2020)
Table 53. China Key Players Influenza (Flu) Antiviral Drugs Revenue (2019-2020) (Million US$)
Table 54. China Key Players Influenza (Flu) Antiviral Drugs Market Share (2019-2020)
Table 55. China Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020) (Million US$)
Table 56. China Influenza (Flu) Antiviral Drugs Market Share by Type (2015-2020)
Table 57. China Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020) (Million US$)
Table 58. China Influenza (Flu) Antiviral Drugs Market Share by Application (2015-2020)
Table 59. Japan Key Players Influenza (Flu) Antiviral Drugs Revenue (2019-2020) (Million US$)
Table 60. Japan Key Players Influenza (Flu) Antiviral Drugs Market Share (2019-2020)
Table 61. Japan Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020) (Million US$)
Table 62. Japan Influenza (Flu) Antiviral Drugs Market Share by Type (2015-2020)
Table 63. Japan Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020) (Million US$)
Table 64. Japan Influenza (Flu) Antiviral Drugs Market Share by Application (2015-2020)
Table 65. Southeast Asia Key Players Influenza (Flu) Antiviral Drugs Revenue (2019-2020) (Million US$)
Table 66. Southeast Asia Key Players Influenza (Flu) Antiviral Drugs Market Share (2019-2020)
Table 67. Southeast Asia Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020) (Million US$)
Table 68. Southeast Asia Influenza (Flu) Antiviral Drugs Market Share by Type (2015-2020)
Table 69. Southeast Asia Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020) (Million US$)
Table 70. Southeast Asia Influenza (Flu) Antiviral Drugs Market Share by Application (2015-2020)
Table 71. India Key Players Influenza (Flu) Antiviral Drugs Revenue (2019-2020) (Million US$)
Table 72. India Key Players Influenza (Flu) Antiviral Drugs Market Share (2019-2020)
Table 73. India Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020) (Million US$)
Table 74. India Influenza (Flu) Antiviral Drugs Market Share by Type (2015-2020)
Table 75. India Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020) (Million US$)
Table 76. India Influenza (Flu) Antiviral Drugs Market Share by Application (2015-2020)
Table 77. Central & South America Key Players Influenza (Flu) Antiviral Drugs Revenue (2019-2020) (Million US$)
Table 78. Central & South America Key Players Influenza (Flu) Antiviral Drugs Market Share (2019-2020)
Table 79. Central & South America Influenza (Flu) Antiviral Drugs Market Size by Type (2015-2020) (Million US$)
Table 80. Central & South America Influenza (Flu) Antiviral Drugs Market Share by Type (2015-2020)
Table 81. Central & South America Influenza (Flu) Antiviral Drugs Market Size by Application (2015-2020) (Million US$)
Table 82. Central & South America Influenza (Flu) Antiviral Drugs Market Share by Application (2015-2020)
Table 83. Pfizer Company Details
Table 84. Pfizer Business Overview
Table 85. Pfizer Product
Table 86. Pfizer Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 87. Pfizer Recent Development
Table 88. Roche Company Details
Table 89. Roche Business Overview
Table 90. Roche Product
Table 91. Roche Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 92. Roche Recent Development
Table 93. Sanofi Company Details
Table 94. Sanofi Business Overview
Table 95. Sanofi Product
Table 96. Sanofi Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 97. Sanofi Recent Development
Table 98. Johnson & Johnson Company Details
Table 99. Johnson & Johnson Business Overview
Table 100. Johnson & Johnson Product
Table 101. Johnson & Johnson Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 102. Johnson & Johnson Recent Development
Table 103. Merck & Co. (MSD) Company Details
Table 104. Merck & Co. (MSD) Business Overview
Table 105. Merck & Co. (MSD) Product
Table 106. Merck & Co. (MSD) Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 107. Merck & Co. (MSD) Recent Development
Table 108. Novartis Company Details
Table 109. Novartis Business Overview
Table 110. Novartis Product
Table 111. Novartis Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 112. Novartis Recent Development
Table 113. AbbVie Company Details
Table 114. AbbVie Business Overview
Table 115. AbbVie Product
Table 116. AbbVie Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 117. AbbVie Recent Development
Table 118. Gilead Sciences Business Overview
Table 119. Gilead Sciences Product
Table 120. Gilead Sciences Company Details
Table 121. Gilead Sciences Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 122. Gilead Sciences Recent Development
Table 123. GlaxoSmithKline (GSK) Company Details
Table 124. GlaxoSmithKline (GSK) Business Overview
Table 125. GlaxoSmithKline (GSK) Product
Table 126. GlaxoSmithKline (GSK) Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 127. GlaxoSmithKline (GSK) Recent Development
Table 128. Amgen Company Details
Table 129. Amgen Business Overview
Table 130. Amgen Product
Table 131. Amgen Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 132. Amgen Recent Development
Table 133. AstraZeneca Company Details
Table 134. AstraZeneca Business Overview
Table 135. AstraZeneca Product
Table 136. AstraZeneca Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 137. AstraZeneca Recent Development
Table 138. Bristol-Myers Squibb Company Details
Table 139. Bristol-Myers Squibb Business Overview
Table 140. Bristol-Myers Squibb Product
Table 141. Bristol-Myers Squibb Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 142. Bristol-Myers Squibb Recent Development
Table 143. Eli Lilly Company Details
Table 144. Eli Lilly Business Overview
Table 145. Eli Lilly Product
Table 146. Eli Lilly Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 147. Eli Lilly Recent Development
Table 148. Teva Company Details
Table 149. Teva Business Overview
Table 150. Teva Product
Table 151. Teva Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 152. Teva Recent Development
Table 153. Bayer Company Details
Table 154. Bayer Business Overview
Table 155. Bayer Product
Table 156. Bayer Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 157. Bayer Recent Development
Table 158. Novo Nordisk Company Details
Table 159. Novo Nordisk Business Overview
Table 160. Novo Nordisk Product
Table 161. Novo Nordisk Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 162. Novo Nordisk Recent Development
Table 163. Allergan Company Details
Table 164. Allergan Business Overview
Table 165. Allergan Product
Table 166. Allergan Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 167. Allergan Recent Development
Table 168. Takeda Company Details
Table 169. Takeda Business Overview
Table 170. Takeda Product
Table 171. Takeda Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 172. Takeda Recent Development
Table 173. Boehringer Ingelheim Company Details
Table 174. Boehringer Ingelheim Business Overview
Table 175. Boehringer Ingelheim Product
Table 176. Boehringer Ingelheim Revenue in Influenza (Flu) Antiviral Drugs Business (2015-2020) (Million US$)
Table 177. Boehringer Ingelheim Recent Development
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Influenza (Flu) Antiviral Drugs Market Share by Type: 2020 VS 2026
Figure 2. Penetration and Dehulling Inhibitors Features
Figure 3. DNA Polymerase Inhibitors Features
Figure 4. Reverse Transcriptase Inhibitors Features
Figure 5. Protein Inhibitors Features
Figure 6. Neuraminidase Inhibitors Features
Figure 7. Broad-spectrum Antiviral Drugs Features
Figure 8. Global Influenza (Flu) Antiviral Drugs Market Share by Application: 2020 VS 2026
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Household Case Studies
Figure 12. Others Case Studies
Figure 13. Influenza (Flu) Antiviral Drugs Report Years Considered
Figure 14. Global Influenza (Flu) Antiviral Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Influenza (Flu) Antiviral Drugs Market Share by Regions: 2020 VS 2026
Figure 16. Global Influenza (Flu) Antiviral Drugs Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Influenza (Flu) Antiviral Drugs Market Share by Players in 2019
Figure 19. Global Top Influenza (Flu) Antiviral Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Influenza (Flu) Antiviral Drugs as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Influenza (Flu) Antiviral Drugs Revenue in 2019
Figure 21. North America Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Pfizer Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 30. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Roche Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 32. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Sanofi Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 34. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Johnson & Johnson Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 36. Merck & Co. (MSD) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Merck & Co. (MSD) Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 38. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Novartis Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 40. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. AbbVie Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 42. Gilead Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Gilead Sciences Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 44. GlaxoSmithKline (GSK) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. GlaxoSmithKline (GSK) Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 46. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Amgen Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 48. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. AstraZeneca Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 50. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Bristol-Myers Squibb Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 52. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Eli Lilly Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 54. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Teva Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 56. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Bayer Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 58. Novo Nordisk Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Novo Nordisk Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 60. Allergan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Allergan Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 62. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Takeda Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 64. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Boehringer Ingelheim Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2015-2020)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed